

## Overview

### Useful For

Assessing compliance or making dosage adjustments for mitotane

### Method Name

Gas Chromatography Mass Spectrometry (GC-MS) Confirmation with Quantitation

### NY State Available

Yes

## Specimen

### Specimen Type

Plasma Na Heparin

### Shipping Instructions

Ship specimen refrigerated.

### Specimen Required

**Collection Container/Tube:** Plain, green-top tube (sodium heparin). Lithium Heparin and Gel tubes **are not** acceptable.

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1 mL

**Collection Instructions:** Centrifuge and aliquot plasma into plastic vial within 2 hours of collection.

### Specimen Minimum Volume

0.5 mL

### Reject Due To

Hemolysis	Mild OK; Gross OK
Thawing**	Warm OK; Cold OK
Lipemia	Mild OK; Gross Reject
Icterus	Mild, OK; Gross OK
List other reasons for rejection	Serum gel tube, Plasma Gel Tube

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
---------------	-------------	------	-------------------

Plasma Na Heparin	Refrigerated (preferred)	21 days	
	Frozen	28 days	
	Ambient	72 hours	

## Clinical & Interpretive

### Clinical Information

This test is intended for the use of therapeutic monitoring of the drug mitotane in patients being treated for adrenal carcinoma. Guidelines suggest monitoring mitotane serum/plasma levels every 2 to 3 weeks for the first 3 months. After reaching a plateau, the interval can be extended (eg, every 6 weeks). Mitotane is a key drug for the treatment of adrenal cortical carcinoma. Due to its narrow therapeutic window (14 to 20 mcg/mL), monitoring its concentration is crucially important.

### Reference Values

Therapeutic: 14-20 mcg/mL

### Interpretation

In the literature when mitotane is used to treat adrenocortical carcinoma, the maximum benefit is seen when plasma mitotane concentrations are between 14-20 mcg/mL.

### Cautions

No significant cautionary statements

### Clinical Reference

1. Feliu C, Cazaubon Y, Guillemin H, et al. Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up. *Biomed Chromatogr.* 2017;31(11):10.1002/bmc.3993. doi:10.1002/bmc.3993
2. Ando M, Hirabatake M, Yasui H, Fukushima S, Sugioka N, Hashida T. A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry. *Biomed Chromatogr.* 2020;34(3):e4776. doi:10.1002/bmc.4776

## Performance

### Method Description

After protein precipitation, mitotane is analyzed by gas chromatography with mass spectrometry.(Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Tuesday, Thursday

### Report Available

---

2 to 7 days

**Specimen Retention Time**

14 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

80299

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
MITAN	Mitotane, P	13626-7

Result ID	Test Result Name	Result LOINC® Value
621811	Mitotane, P	13626-7